The recognition in 2019 of the first outbreak in Wuhan, China, of a respiratory disease (COVID‐19) associated with a novel coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) triggered an international response unparalleled in its scale and tempo.1, 2, 3, 4, 5, 6 In particular, the rapid sharing and integration of clinical and epidemiological data has facilitated understanding of the spectrum of clinical disease caused by SARS‐CoV‐2 and the extent of its global spread, although there are still many unanswered questions.
In China, he had had no contact with live food markets, people known to have COVID‐19, or hospitals.
Our sequences are available at GenBank (accession number, MT007544.1), and the genome was rapidly uploaded to the Global Initiative of Sharing All Influenza (GISAID) (accession number, EPI_ISL_406844).
We have described the first reported case of COVID‐19 in Australia, with rapid diagnosis, and isolation, imaging, and sharing of the causative agent, SARS‐CoV‐2.
Major outcomes  Clinical course and laboratory features of the first reported case of COVID ‐19 (the illness caused by SARS ‐CoV‐2) in Australia; isolation, whole genome sequencing, imaging, and rapid sharing of virus from the patient.